Sign In
Buy BNTX
$92.18
+0.83 (+0.91%)
At Close: Aug 05, 2026
What's Going On With Moderna, BioNTech And Novavax Stock Today
03:26pm, Thursday, 13'th Jan 2022
Shares of vaccine makers, including Moderna Inc (NASDAQ:MRNA), BioNTech SE – ADR (NASDAQ:BNTX) and Novavax, Inc. (NASDAQ:NVAX), are all trading lower as the sector continues to pull back followi
Why Shares of BioNTech Rose 216% in 2021
11:49am, Thursday, 13'th Jan 2022
The successful rollout of a revolutionary vaccine leaves the immunotherapy specialist primed for further gains.
BioNTech (BNTX) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference
09:22pm, Wednesday, 12'th Jan 2022 Seeking Alpha
IBD/TIPP Poll: Will Pediatric Shots Extend Pfizer, BioNTech Streak?
02:35pm, Wednesday, 12'th Jan 2022 Investor''s Business Daily
Vaccine stocks could enjoy a longer Covid runway. Roughly six in 10 adults support Covid shots for children, according to the IBD/TIPP Poll.
Why did BioNTech stock dip today? 2022 outlook for COVID-19 vaccine sales
09:26pm, Tuesday, 11'th Jan 2022 Seeking Alpha
BioNTech <> extended YTD decline with another intraday loss today after issuing its projection for COVID-19 vaccine sales for this year, the lower margin of which fell short of
BioNTech Partners With London-Based AI Developer To Predict COVID-19 Variants
06:52pm, Tuesday, 11'th Jan 2022 Benzinga
BioNTech SE (NASDAQ: BNTX ) said its working with London-based AI developer InstaDeep to develop a new computational method that analyzes sequencing data and predicts high-risk variants SARS-CoV-2 . The early warning system combines structural modeling of the SARS-CoV-2 spike protein, and Full story available on Benzinga.com
BioNTech SE (BNTX) CEO Ugur Sahin on JPMorgan 40th Annual Healthcare Conference (Transcript)
03:34pm, Tuesday, 11'th Jan 2022
BioNTech SE (BNTX) CEO Ugur Sahin on JPMorgan 40th Annual Healthcare Conference (Transcript)
BioNTech Partners With London-Based AI Developer To Predict COVID-19 Variants
01:52pm, Tuesday, 11'th Jan 2022
BioNTech SE (NASDAQ: BNTX) said it's working with London-based AI developer InstaDeep to develop a new computational method that analyzes sequencing data and predicts high-risk variants SARS-CoV-2.
New Strong Buy Stocks for January 11th
09:14am, Tuesday, 11'th Jan 2022
ANF, ARCO, BNTX, GSL, and KLIC have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2022.
BioNTech eyes up to 17 billion euros in vaccine revenue in 2022
08:17am, Tuesday, 11'th Jan 2022
Germany's BioNTech said on Tuesday it would likely generate up to 17 billion euros ($19 billion) in 2022 revenue from the COVID-19 vaccine it co-developed with partner Pfizer.
BioNTech, InstaDeep create new system to identify high risk SARS-CoV-2 variants
07:26am, Tuesday, 11'th Jan 2022
Shares of BioNTech SE BNTX, +8.57% were down 0.6% in premarket trading on Tuesday after the company said it developed a new system with InstaDeep Ltd. that uses a mix of modeling and artificial intell
Why BioNTech Stock Jumped Today
09:27pm, Monday, 10'th Jan 2022 The Motley Fool
Two developments contributed to the stock''s nice gain.
Why BioNTech Stock Jumped Today
04:27pm, Monday, 10'th Jan 2022
Two developments contributed to the stock's nice gain.
BioNTech, Crescendo Bio collaborate to develop multi-specific precision immunotherapies
02:58pm, Monday, 10'th Jan 2022 Seeking Alpha
BioNTech <> and Crescendo Biologics have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and
The Week Ahead In Biotech (Jan 10-15): JPMorgan Healthcare Conference Front And Center, Preannouncements Keep Coming
12:41pm, Monday, 10'th Jan 2022 Benzinga
Biotech stocks came under selling pressure along with the broader market, as rate hike fears seized Wall Street. The news flow, however, was scanty. Last week, the Food and Drug Administration expanded the emergency use authorization it accorded for the Pfizer, Inc. (NYSE: PFE )- BioNTech SE (NASDAQ: BNTX ) vaccine. The expanded approval allows the use of a single booster dose in individuals 12 through 15 years of age, a third primary series dose for certain immunocompromised children 5 through 11 years of age, and the shortening of time between completion of primary vaccination and a booster dose to at least five months. Clinical readouts resulted in contrasting stock moves. Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT ) ended the week up about 80% after its lead candidate LB-100 was found to increase the responsiveness of diverse cancers to immunotherapy. On the other hand, Aligos Therapeutics, Inc. (NASDAQ: Full story available on Benzinga.com
